MWVC
ALNY icon

Morgens Waterfall Vintiadis & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,000
Closed -$1.08M – 22
2025
Q1 		$1.08M Buy
+4,000
New +$1.03M 1.22% 16

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's ALNY Position: Q2 2025 in Review

Morgens Waterfall Vintiadis & Co sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2025, closing a stake of 4,000 shares — an estimated $1.08M sold.

Morgens Waterfall Vintiadis & Co first reported a position in ALNY in Q1 2025 and held it in 1 quarter. The position peaked at $1.08M in Q1 2025. 654 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

  • Morgens Waterfall Vintiadis & Co reported no remaining Alnylam Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 4,000 Alnylam Pharmaceuticals shares in Q2 2025, an estimated $1.08M.
  • Morgens Waterfall Vintiadis & Co first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Morgens Waterfall Vintiadis & Co's Alnylam Pharmaceuticals position peaked at $1.08M in Q1 2025.
  • 654 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q2 2025, filed 14 Aug 2025.